Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endeavor study in chronic hepatitis B after entecavir-induced HBeAg seroclearance
ChiCTR-TRC-13003249Phase 4Completed
- Sponsor
- Tongji Hospital
- Start
- Jun 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon alfa-2b, aldesleukin, Hepatitis B vaccine and entecavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Tongji Hospital. Primary endpoint: Quantitative determination of serum hepatitis B markers. Started Jun 2013; status: completed.
02
Drugs
interferon alfa-2baldesleukinHepatitis B vaccineentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-TRC-13003249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003249.